Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026

Imported from official source

Announcement

Safety Classified by Officially

PRAC starts review of depression and anxiety medicine Deanxit (flupentixol/melitracen)

PRAC has started a review of Deanxit, a fixed-dose combination medicine for treating depression and anxiety, following reports of serious neurological and psychiatric side effects in patients taking the medicine.

The reports concern cases involving movement disorders, such as tremors, stiffness, restlessness and involuntary movements, and memory and thinking problems. In some cases, symptoms persisted after treatment was stopped. 

More information is available in EMA’s start of referral communication.

PRAC reviews increased reporting of allergic reactions with specific batches of human normal immunoglobulin medicines

PRAC has started a review of a safety signal concerning increased reporting of hypersensitivity (allergic) reactions associated with specific batches of human normal immunoglobulin medicines.

Human normal immunoglobulins are used to help prevent infections in people who do not have enough antibodies, including those with certain immune disorders or blood cancers. They are also used to treat some conditions in which the immune system attacks the body’s own tissues.

Hypersensitivity reactions are a known side effect of these medicines. Their product information includes warnings that serious hypersensitivity reactions can occur, even in patients who have previously tolerated treatment. However, reports indicate that hypersensitivity reactions may be occurring more frequently than expected with specific batches of some human normal immunoglobulin medicines.

This is an extract. The publication continues at the source.

Source: European Medicines Agency.

Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-26-29-october-2026

Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
European Medicines Agency — imported from official source
Official source
https://www.ema.europa.eu/en/news.xml RSS
Imported
October 30, 2026 12:00
Versions
1 recorded
Identity
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.